Therapeutic Utility of Germline Variants Is an "Open Question"

Jane De Lartigue, PhD
Published: Friday, Jul 05, 2019
Hannah Carter, PhD

Hannah Carter, PhD

Although heritable mutations have been implicated in cancer risk, the role that these aberrations play in the development of malignancies with acquired mutations is a question that will require studies of large data sets of patients, according to Hannah Carter, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication